Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To compare the pharmacokinetics (PK), pharmacodynamics (PD), and safety profile of intravenous (IV) and oral formulation of fexuprazan 40 mg in healthy subjects

Next Previous
Trial Profile

To compare the pharmacokinetics (PK), pharmacodynamics (PD), and safety profile of intravenous (IV) and oral formulation of fexuprazan 40 mg in healthy subjects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fexuprazan (Primary) ; Fexuprazan (Primary)
  • Indications Bleeding ulcer; Erosive oesophagitis; Gastritis; Gastro-oesophageal reflux; Peptic ulcer
  • Focus Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 18 Aug 2022 New trial record
  • 28 Jun 2022 Results presented at the 15th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top